<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829151</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-1104</org_study_id>
    <nct_id>NCT02829151</nct_id>
  </id_info>
  <brief_title>Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Prospective, randomized, controlled, multi-center study

        -  A total of 390 subjects with critical limb ischemia will be included according to
           inclusion and exclusion criteria.

        -  Patients will be randomized in a 1:1:1 manner into triple antiplatelet therapy (TAP:
           aspirin, clopidogrel, cilostazol) group, dual antiplatelet therapy (DAP: aspirin,
           clopidogrel) A group, or DAP (aspirin, cilostazol) B group.

        -  All patients will be treated with angioplasty for critical limb ischemia.

        -  Patients will be followed clinically for 1 year after the procedure.

        -  Ankle-brachial index and Image study follow-up (Duplex US or CT angiography) will be
           performed at 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>A composition event of all-cause death, myocardial infarction, stroke, repeat revascularization of the target lesion, and unexpected amputation of the target limb between TAP group and DAP A group (aspirin &amp; clopidogrel)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse event between TAP group and DAP B group</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse limb event among the 3 patient groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications among the patient groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Triple antiplatelet therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient group with triple antiplatelet therapy using aspirin, clopidogrel, and cilostazol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAP (Dual antiplatelet therapy) A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient group with dual antiplatelet therapy using aspirin and clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAP (Dual antiplatelet therapy) B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient group with angioplasty using aspirin and cilostazol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )</intervention_name>
    <description>Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty</description>
    <arm_group_label>Triple antiplatelet therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel</intervention_name>
    <description>Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty</description>
    <arm_group_label>DAP (Dual antiplatelet therapy) A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol</intervention_name>
    <description>Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty</description>
    <arm_group_label>DAP (Dual antiplatelet therapy) B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients â‰¥ 19 years old

          -  Patients with critical limb ischemia (Rutherford 4 &amp; 5)

          -  Successful below-the knee endovascular intervention.

        Exclusion Criteria:

          -  Major bleeding event within recent 3 months or high risk of major bleeding

          -  Patients requiring anticoagulation

          -  Allergic reactions to antiplatelet drugs

          -  Acute limb ischemia

          -  Severe hepatic dysfunction (3 times normal reference values)

          -  Pregnant women or women with potential childbearing

          -  Life expectancy &lt; 1 year due to comorbidity

          -  Previous amputations in the target limb
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral artery disease</keyword>
  <keyword>Critical limb ischemia</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

